Form 4: Enliven Therapeutics CFO Benjamin Hohl Reports Stock Option Exercises and Sales

Benjamin Hohl, CFO of Enliven Therapeutics, executed stock option exercises and sales on December 27 and December 30, 2024, according to a Form 4 filing.

Summary

• Benjamin Hohl, the CFO of Enliven Therapeutics, Inc., reported changes in beneficial ownership of the company's stock.
• On December 27, 2024, Hohl exercised options to acquire 3,350 shares of common stock at a price of $2.48 per share and then sold those shares at a weighted average price of $22.1549.
• On December 30, 2024, Hohl exercised options to acquire 900 shares of common stock at a price of $2.48 per share and then sold those shares at a weighted average price of $22.5061.
• These transactions were executed under a pre-arranged Rule 10b5-1 trading plan adopted on June 26, 2023.
• Following these transactions, Hohl directly owns 164,306 derivative securities.

Sentiment

Score: 5

Explanation: This is a routine disclosure of insider trading activity. The sentiment is neutral as it doesn't inherently indicate positive or negative news about the company's performance.

Industry Context

Form 4 filings are standard disclosures required by the SEC when company insiders, like the CFO, trade their company's stock. These filings provide transparency to the market.

Stakeholder Impact

• Shareholders are informed about insider trading activities, providing transparency into management's actions.

Key Dates